2020 GA Meeting May 6th Postponed to November 4th due to COVID 19


The 2019 GA meeting which took place on Wednesday 8 May 2019 in Madrid, Spain was a resounding success. Hosted by FerroGlobe, the meeting which lasted 4 hours saw several deliberations related to the consortium governace, dossier updates and classification & labelling. Some key decisions taken by way of vote are as follows:

Some highlights:

  • Executive Committee: A new Chairmanand  a new 2nd Vice Chairman were appointed, meanwhile the 1st Vice Chiarman was maintained to enure continuity
  • Dossier updates: Reveal changes in classification and labelling if compared to the 2010 submitted dossiers
  • Approval of the 2018 workplan and budget
  • Brexit and data: Mara will continue to support REACH registration inside and outside the EU (UK REACH inclusive) but at a charge yet to be determined

Prenatal Developmental toxicity study in the rat/FeMn slag/OECD 414/oral/GLP


The purpose of this study was an assessment of the influence of FeMn Slag (ferromanganese slag), a by-product of the production of manganese alloys, on embryo-fetal survival and development when administered during the organogenesis and fetal growth phases of pregnancy in the rat. Three groups of 20 females received FeMn Slag at doses of 100, 330 or 1000 mg/kg/day by oral gavage administration, from Day 6 to 19 after mating. A similarly constituted Control group received the vehicle, corn oil, at the same volume dose as treated groups. Animals were killed on Day 20 after mating for reproductive assessment and fetal examination. Clinical observations, body weight and food consumption were recorded. Adult females were examined macroscopically at necropsy on Day 20 after mating and the gravid uterus weight recorded. All fetuses were examined macroscopically at necropsy and subsequently by detailed internal visceral examination or skeletal examination.


There were no unscheduled deaths, no signs associated with dosing, no adverse treatment related clinical signs, effects on body weight or food consumption and no findings detected at necropsy of the dams. All animals receiving FeMn slag were pregnant. There was no effect on embryo-fetal survival growth or development. Slightly high placental weights (up to 111% of control) were recorded, attaining statistical significance at the 330 and 1000 mg/kg/day dose levels, but the magnitude of the difference was considered not to be adverse.


In this study ferromanganese slag was well tolerated and the maternal no observed adverse effect level (NOAEL) was concluded to be 1000 mg/kg/day. There was no adverse effect on embryo-fetal survival, development or growth, therefore the embryo-fetal no observed adverse effect level (NOAEL) was considered to be 1000 mg/kg/day

« Back to studies

About cookies on our website

Following a revised EU directive on website cookies, each company based, or doing business, in the EU is required to notify users about the cookies used on their website.

Our site uses cookies to improve your experience of certain areas of the site and to allow the use of specific functionality like social media page sharing. You may delete and block all cookies from this site, but as a result parts of the site may not work as intended.

To find out more about what cookies are, which cookies we use on this website and how to delete and block cookies, please see our Which cookies we use page.

Click on the button below to accept the use of cookies on this website (this will prevent the dialogue box from appearing on future visits)